The size of the global bioreactors market is expected to be worth USD 1850.96 million by 2027, from USD 1327.75 million in 2022. This market is estimated to be growing at a CAGR of 6.87% during the forecast period. Rising Chronic disease prevalence and increasing biopharmaceutical investments propel the global bioreactors market growth.
Bioreactors are used to manufacture biochemically active substances through a chemical process in a vessel. The device's design is an engineering task where it involves monitoring the optimum conditions that enable the performance level. Bioreactors help to grow cells or tissues, and also these are specially designed with the help of biochemical engineering. This technique follows three stages to form the finished product from the raw materials. The selection of raw material for the appropriate application is also an important task. These devices also keep the cell's inhomogeneous state to obtain the desired output.
Y-O-Y growth in the adoption of single-use technologies and hybrid technologies is expected to drive the global bioreactors market growth.
Bioreactors are in high demand due to single-use and stainless steel, increasing popularity among biopharmaceutical businesses as single-use bioreactors and biologics. The expansion of bioreactors in the pharmaceutical industry is a significant driver driving the market growth. In addition, high operational costs and a lack of traditional servicing and control are further reasons driving global market expansion.
Innovative approaches and analytical tools should improve process resilience, speed up scale-up to industrial production, and increase resource efficiency. In addition, ineffective waste management due to the extensive usage of hybrid bioreactor engineering will also allow the bioreactor market to grow.
The adoption of single-use bioreactors (SUBs) and hybrid bioreactors and the rise of bioreactors in pharmaceuticals are other key drivers of the bioreactors market.
Biopharmaceuticals are used in various ways, from biopharmaceutical synthesis to tissue engineering applications like cell growth and 3D tissue construct generation. Therefore, bioreactors are used to provide a controlled environment for any cells or cellular constructions introduced into them in terms of pH, temperature, food delivery, and shear stress. In addition, bioreactors have been used to develop in vitro models of 2D cultures and suspensions to 3D structures, simulating the natural physiological state in situ. As a result, they effectively treat autoimmune illnesses, cancer, asthma, and organ rejection. As a result, the pharmaceutical industry's expansion of bioreactors is a primary driver of market growth.
Furthermore, advances in bioreactor technology have enhanced the flexibility, quality, and scalability of operations with minimal capital and energy costs. The novel approaches and analytical tools are expected to improve process resilience, speed up scale-up to industrial production, and promote resource efficiency. In addition, the widespread application of hybrid bioreactor technology in effective waste management has aided the market's growth.
Regulatory concerns relating to single-use bioreactors and leachable and extractable issues relating to single-use bags impede the growth of this industry. Besides, the processing of plastic derivatives on a large scale is an environmental concern that restricts the global bioreactors market growth.
Impact of COVID-19 on the global bioreactors market:
Coronavirus (COVID 19) is caused by the SARS-CoV-2 reagent and has spread to all parts of the world, and the World Health Organization (WHO) has declared the COVID-19 a pandemic. Millions of people are affected by COVID, and many biopharmaceutical companies are quickly advancing the techniques in improving vaccines in response to the pandemic crisis. For instance, Moderna Therapeutics has a messenger RNA in Phase I trials, and Inovio Pharmaceuticals has a DNA vaccine that has entered human trials. The market-leading manufacturers of bioreactors are working with the companies in developing the vaccine or already existing in the clinical test stages. For instance, Sartorius supported CanSino Biologics Inc. and Maj. In China, Gen Chen Wei's team at the Institute of Bioengineering at the Academy of Military Medical Sciences is developing their first vaccine candidate against the novel coronavirus in entering clinical trials. The world's largest vaccine manufacturer in India, Serum Institute, agreed to manufacture 1 billion doses of Novavax's -vaccine NVX-CoV2373 by 2021. Serum Institute is the largest single-use bioreactor-based vaccine manufacturing company in the world. The Serum Institute of India has received six 4,000L CSR bioreactors from ABEC to help it scale up the manufacture of Novavax's COVID 19 vaccine candidate.
Market Size Available
2021 to 2027
2022 to 2027
By Material, Production, Supplies, Scale, Control Type, End-User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints. Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
This research report on the global bioreactors market has been segmented and sub-segmented based on the material, production, supplies, scale, control type, end-user, and region.
Bioreactors Market – By Material:
Based on material, The single-use bioreactors segment is anticipated to show the highest growth by volume. Rapid growth in this segment is attributed to the benefits of SUBs, such as the decreased need for cleaning and sterilization, reduced risk of cross-contamination, and increased control of aseptic conditions. In addition, SUBs increase end-product quality by reducing the complexity of automation.
Bioreactors Market – By Scale:
Based on the scale, the 20L-200L scale type dominates the market with the highest share. The rise in capital income in both developed and developing countries greatly influences the market's demand.
Bioreactors Market – By Production:
Bioreactors Market – By Control Type:
Based on control Type, the automatic control form segment has accounted for the largest market share for bioreactors in terms of volume. However, the preference for mass flow controllers (MFCs) is increasing in the current scenario, resulting in the use of an automated type of control. It is because they are adding additional security protection and increasing bioreactors' operating costs. In addition, it doesn't take skilled labor to operate bioreactors on MFCs. As a result, an increasing number of firms opt for MFCs.
Bioreactors Market – By End-users:
Due to the increased use of bioreactors in process development, the R&D segment is expected to report the highest growth rate during the forecast period. On the other hand, it is anticipated that contract manufacturing organizations (CMOs) will gain traction in the coming years due to increased outsourcing needs for biologics manufacturers due to increased demand for biologics.
Bioreactors Market – By Suppliers:
Since OEMs not only supply the machines, the piping and installation, instrumentation, programming, and control are also set up. As a result, OEMs are expected to account for a more significant market share than EPCs.
Bioreactors Market – By Region:
Geographically, the North American bioreactors market occupied the largest share of the global bioreactors market, and this dominance is projected to last for a few more years. Because of increased cooperation between industry and academic institutions, this area is likely to grow its market share. Because pharmaceuticals and high-tech product manufacturers have announced multimillion-dollar expenditures to enhance production capacities, the United States owns the majority of the market in the North American region.
Furthermore, the United States and Canada, two of the region's major countries, invest heavily in research and development. For example, the United States spent roughly USD 7,767 million on biotechnology research in 2020, according to the National Centre for Health Statistics (NCHS) of the Centres for Disease Control and Prevention (CDC). They also predicted that by 2022, this figure would have risen to USD 7,912 million. The large sums spent are projected to drive market growth since they increase demand for new pharmaceuticals and pharmaceutical ingredients produced in bioreactors.
Domestic enterprises are using a variety of measures to increase their market position, including R&D, mergers and acquisitions, and product launches. In September 2019, for example, ABEC Inc., a biopharmaceutical business, announced the debut of a single-use bioreactor system with a working volume of 6,000 L. According to the business, this amount was more than three times the industry's normal top limit at the time. In addition, Thermo Fisher Scientific launched the HyPerforma DynaDrive 3,000 L and HyPerforma DynaDrive 5,000 L single-use bioreactors in March 2021 in response to increased demand for large-scale single-use systems. These product introductions are projected to boost market growth over the forecasted period.
Furthermore, the market is likely to benefit from increased demand for biopharmaceutical goods in the region and a focus on expanding localized production over the forecast period.
During the projected period, the European bioreactors market was the second largest region, accounting for the highest part of the global market. Government policies, research and & development initiatives, and private financing are projected to offer new opportunities for the bioreactors market in this area. Bioreactors have been created in Europe by biotechnology and pharmaceutical companies. The pharmaceutical industry in Europe is seeing an increase in demand for single-use bioreactors to synthesize new medicinal drugs.
Because of the use of new technology to develop innovative goods, the United Kingdom Bioreactors Market holds the most significant proportion of the market. In addition, companies that make bioreactors in Spain have a robust and well-connected network with other industries. Therefore, they provide customers with well-integrated modern bioreactors according to their needs. One aspect that contributes to the market's growth is consistent economic growth. Following in the footsteps of the UK, the German Bioreactors market is driving toward market dominance. The bioreactor market is being evaluated due to the increased prevalence of chronic diseases and the rising demand for high-quality treatment. In addition, increased investment in pharmaceutical businesses is growing demand for this industry.
The APAC bioreactors market is predicted to be growing at a CAGR of 8.12% from 2022 to 2027.
The bioreactors market in Latin America is projected to grow by USD 149.55 million in 2022.
The Middle East and Africa bioreactors market is expected to be worth USD 139.6 million by 2027.
KEY MARKET PLAYERS:
The bioreactor market is moderately competitive, with only a few significant players. Only a few significant players presently control the market in terms of market share. Due to technological developments and product innovation, mid-size and smaller enterprises increase their market share by releasing new things at lower rates.
Notable market participants leading the global bioreactors market profiled in this report are Sartorius AG, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, Danaher Corporation, and Eppendorf AG. In addition, this report's procurement and Construction (EPC) players are Amec Foster Wheeler plc, Fluor Corporation, Jacobs Engineering Group Inc., M+W Group, PM Group, and Technip S.A.
RECENT MARKET DEVELOPMENTS:
As per our research report, the global bioreactors market size is estimated to be worth USD 1850 million by 2027.
From 2022 to 2027, the global market for bioreactors market is projected to be growing at a CAGR of 6.87%.
Yes, we have studied and included the COVID-19 impact on the global bioreactors market in this report.
Sartorius AG, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, Danaher Corporation, and Eppendorf AG. In addition, this report's procurement and Construction (EPC) players are Amec Foster Wheeler plc, Fluor Corporation, Jacobs Engineering Group Inc., M+W Group, PM Group, and Technip S.A. are some of the key players in the global bioreactors market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com